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while our patient had low IgG (1.76 g/L) and IgA
(0.28 g/L). We could speculate that humoral dys-
function related to rituximab therapy could have
caused loss neutralization of free viral particles by
specific antibodies, facilitating initial dissemination
of the VZV but this hypothesis needs to be investi-
gated further.
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Cyclosporine treatment of acquired hemophil-
ia due to factor VIII antibodies
Acquired hemophilia, caused by autoantibodies
against coagulation factor VIII, is usually treated
with steroids, cyclophosphamide, intravenous gam-
maglobulins and sporadically other drugs. We
describe the case of a patient in whom the common
therapeutic choice was unsuccessful, but cyclo-
sporine proved to be effective.
Sir,
A 56-year old man with chronic obstructive pul-
monary disease was admitted because of hemopty-
sis. There was no evidence of malignancy, tuberculo-
sis or autoimmune disorders. The patient did not
take any new drug before admission. Routine coag-
ulation tests showed repeatedly a prolongation of
the activated partial thromboplastin time (to 63.7
sec, upper normal value 37 sec). This was due to a
decrease of factor VIII:C to 0.04 IU/mL with an anti-
body level against factor VIII of 40 Bethesda
units/mL. An acquired von Willebrand syndrome was
excluded (vWF:Ag of 2.38 IU/mL, vWF:Rco of 1.23
IU/mL). Treatment during 3 months with prednisone
(initially 1 mg/kg/day) and cyclophosphamide 50 mg
p.o. daily, followed by i.v. gammaglobulins (0.4
g/kg/day for 5 days) had no influence on the pres-
ence of the antibodies. Later on a subcutaneous hem-
orrhage in the left arm and bleeding in the sural mus-
cles of the right leg occurred. During that period
recombinant activated factor VII was successfully
administered. After initiation of cyclosporin, the anti-
bodies against factor VIII progressively decreased and
finally disappeared. The treatment was stopped after
eight months. The coagulation tests remained nor-
mal. Spontaneously acquired antibodies against fac-
tor VIII are infrequent. They peak in the third and sev-
enth decades.1 Intramuscular bleeds are the most
common hemorrhagic manifestation. The major
cause of acquired antibodies against factor VIII,
excluding hemophilia, are autoimmune disorders,
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Figure 1. Mesothelial cell with cytopathic changes sug-
gestives of herpes virus infection.
malignant diseases, pregnancy or drug reactions. In
about 50% of the cases no underlying disease can be
identified. The prognosis is poor if untreated. Spon-
taneous disappearance of the inhibitor has been
reported, but after a long delay. Acute bleeding peri-
ods can be treated with recombinant activated fac-
tor VII, as in hemophiliacs with inhibitors. Alterna-
tives include large doses of factor VIII, a porcine fac-
tor VIII, prothrombin complex concentrates (PCC)
and activated PCC. The most frequently used treat-
ments for elimination of the antibodies include oral
corticosteroids and cyclophosphamide. A high dose
of i.v. gammaglobulins can also be effective.2 The
alternatives are interferon, a combination of steroids,
cyclophosphamide and vincristine, or combination
chemotherapy. The effect of replacement therapy or
removing antibodies by plasmapheresis is only tran-
sient.2,3 The experience with cyclosporine shows that
it might be effective in the treatment of acquired
hemophilia with a high antibody titer against factor
VIII.3 Cyclosporine inhibits cell-mediated reactions
and plays a role in the induction of immune toler-
ance against factor VIII. It does not affect
hematopoiesis and causes fewer infectious compli-
cations.4 This drug could be considered as a possible
treatment of acquired hemophilia if other modalities
fail.
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